NCT06904066
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 364 versions: 50 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Start date changed from estimate of Nov 4, 2026 to Oct 28, 2026
- Minor Start date: Nov 3, 2026 to Nov 4, 2026
- Minor Start date: Nov 2, 2026 to Nov 3, 2026
- Minor Start date: Nov 1, 2026 to Nov 2, 2026
- Minor Start date: Oct 29, 2026 to Nov 1, 2026
Show 45 earlier versionsHide 45 earlier versions
- Minor Start date: Oct 28, 2026 to Oct 29, 2026
- Minor Start date: Oct 27, 2026 to Oct 28, 2026
- Minor Start date: Oct 26, 2026 to Oct 27, 2026
- Minor Start date: Oct 25, 2026 to Oct 26, 2026
- Minor Start date: Oct 22, 2026 to Oct 25, 2026
- Minor Start date: Oct 21, 2026 to Oct 22, 2026
- Minor Start date: Oct 20, 2026 to Oct 21, 2026
- Minor Start date: Oct 19, 2026 to Oct 20, 2026
- Minor Start date: Oct 18, 2026 to Oct 19, 2026
- Minor Start date: Oct 14, 2026 to Oct 18, 2026
- Minor Start date: Oct 13, 2026 to Oct 14, 2026
- Minor Start date: Oct 12, 2026 to Oct 13, 2026
- Notable Eligibility criteria expanded, about 16 words
- Start date: Oct 11, 2026 to Oct 12, 2026
- Study description shortened, about 4 words
- Minor Start date: Oct 8, 2026 to Oct 11, 2026
- Minor Start date: Oct 7, 2026 to Oct 8, 2026
- Minor Start date: Oct 6, 2026 to Oct 7, 2026
- Minor Start date: Oct 5, 2026 to Oct 6, 2026
- Minor Start date: Oct 4, 2026 to Oct 5, 2026
- Minor Start date: Sep 20, 2026 to Oct 4, 2026
- Minor Start date: Sep 17, 2026 to Sep 20, 2026v340
- Minor Start date: Sep 16, 2026 to Sep 17, 2026v339
- Minor Start date: Sep 15, 2026 to Sep 16, 2026v338
- Minor Start date: Sep 14, 2026 to Sep 15, 2026v337
- Minor Start date: Sep 10, 2026 to Sep 14, 2026v336
- Minor Start date: Sep 9, 2026 to Sep 10, 2026v335
- Minor Start date: Sep 8, 2026 to Sep 9, 2026v334
- Minor Start date: Sep 7, 2026 to Sep 8, 2026v333
- Minor Start date: Sep 6, 2026 to Sep 7, 2026v332
- Minor Start date: Sep 3, 2026 to Sep 6, 2026v331
- Minor Start date: Sep 2, 2026 to Sep 3, 2026v330
- Minor Start date: Sep 1, 2026 to Sep 2, 2026v329
- Minor Start date: Aug 31, 2026 to Sep 1, 2026v328
- Minor Start date: Aug 30, 2026 to Aug 31, 2026v327
- Minor Start date: Aug 27, 2026 to Aug 30, 2026v326
- Minor Start date: Aug 26, 2026 to Aug 27, 2026v325
- Minor Start date: Aug 25, 2026 to Aug 26, 2026v324
- Minor Start date: Aug 24, 2026 to Aug 25, 2026v323
- Minor Start date: Aug 23, 2026 to Aug 24, 2026v322
- Minor Start date: Aug 20, 2026 to Aug 23, 2026v321
- Minor Start date: Aug 19, 2026 to Aug 20, 2026v320
- Minor Start date: Aug 18, 2026 to Aug 19, 2026v319
- Minor Start date: Aug 17, 2026 to Aug 18, 2026v318
- Minor Start date: Aug 16, 2026 to Aug 17, 2026v317
- Minor Start date: Aug 13, 2026 to Aug 16, 2026v316
- Minor Start date: Aug 12, 2026 to Aug 13, 2026v315
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Safety
Timeframe: From time of the lymphodepleting chemotherapy through 5 years after neoepitope-specific T cell infusion or until off study.
Secondary (2)
Overall response rate
Feasibility of manufacturing and administering neoepitope-specific T cells
Arms and interventions
1/Experimental: No allo-HSCTExperimental
Preparative regimen of cyclophosphamide and fludarabine + infusion of neoepitope-specific T cells (of up to 1.5x10\^11 total cells) + aldesleukin.
2/Experimental: prior allo-HSCTExperimental
Preparative regimen of cyclophosphamide and fludarabine + infusion of neoepitope-specific T cells (at a dose of 1x10\^10 total cells) + aldesleukin.
Drugs: aldesleukin, cyclophosphamide, fludarabine phosphate
Biologicals: Individual Patient TCR-Transduced PBL
Devices: TruSight Oncology (TSO) 500
Sites
1 site in 1 country
- National Institutes of Health Clinical CenterBethesda, Maryland, United States